Otsuka
As of the edition of 20 October 2026, Otsuka runs 82 drugs, 37 of them marketed; it is on route A at 13 targets and on route B at 18 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 8 company names in this family.
- Supergen Inc: renamed in 2011
- Astex Pharmaceuticals, Inc.: acquired in 2013; successor EN Otsuka Pharmaceutical Co., Ltd.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 37 |
| Active | 9 |
| Went quiet | 13 |
| Stopped | 15 |
| Withdrawn from market | 1 |
| Status not established | 7 |
| Total | 82 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Busulfan | none listed | 0 |
| Decitabine | none listed | 4 |
| Sodium chloride | none listed | 0 |
| Aripiprazole | none listed | 3 |
| Mitomycin | none listed | 0 |
| Dextrose | none listed | 0 |
| Latanoprost | none listed | 5 |
| Saxagliptin anhydrous | Ends 2027 (exclusivity) | 2 |
| Cilostazol | none listed | 2 |
| Tolvaptan | Ended 2026 (patent) | 0 |
| Brexpiprazole | Ends 2028 (patent) | 2 |
| Rotigotine | none listed | 5 |
| Cedazuridine | Ends 2034 (patent) | 1 |
| Mannitol | none listed | 0 |
| Water | none listed | 0 |
| Ponatinib | Ends 2033 (patent) | 1 |
| Bempedoic acid | Ends 2040 (patent) | 3 |
| Potassium chloride | none listed | 0 |
| Rebamipide | none listed | 0 |
| Fremanezumab | Ends 2030 (computed from the first US licence) | 4 |
| Nalmefene | none listed | 9 |
| Amino acids | none listed | 0 |
| Delamanid | none listed | 0 |
| Centanafadine | none listed | 0 |
| Levocarnitine | none listed | 0 |
A route B row is one company at one target. 12 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 13 targets, route B at 18 targets.
All 31 rows on route A or B
In the product31 company-target rows on route A or B; 28 are not shown here, and no score is.
See all 31 targets where Otsuka needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mental health: 169 trials led
- Nervous system: 46 trials led
- Cancer: 45 trials led